SCHEMBL1165261

SCHEMBL1165261

C=Cc1ccc2ncn(-c3ccc4c(c3)CCN4C(=O)OC(C)(C)C)c2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 3/20 0.40
▸ GPR119 Q8TDV5 6/20 0.36
▸ MPO P05164 1/20 0.36
▸ ATM Q13315 3/20 0.35
▸ DHODH Q02127 1/20 0.35
▸ CHRM4 P08173 1/20 0.35
▸ DRD2 P14416 1/20 0.35
▸ HTR7 P34969 1/20 0.35
▸ USP30 Q70CQ3 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ GABRP O00591 1/20 0.34
▸ GABRD O14764 1/20 0.34
▸ GABRA1 P14867 1/20 0.34
▸ GABRB1 P18505 1/20 0.34
▸ GABRG2 P18507 1/20 0.34
▸ GABRB3 P28472 1/20 0.34
▸ GABRA5 P31644 1/20 0.34
▸ GABRA3 P34903 1/20 0.34
▸ GABRA2 P47869 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1165238 0.93 ATM (0.40) ATMCHRM4DRD2HTR7
SCHEMBL1165184 0.92 CYP11B2 (0.41) CYP11B2GPR119MPOATMDHODH
SCHEMBL1166009 0.87 CYP11B2 (0.53) CYP11B2ALDH1A1HPGD
SCHEMBL1165188 0.86 CYP11B2 (0.42) CYP11B2GPR119MPOATMDHODH
SCHEMBL1165229 0.85 ATM (0.41) ATMCHRM4DRD2HTR7ALDH1A1
SCHEMBL1165473 0.84 GPR119 (0.39) CYP11B2GPR119MPOATMDHODH
SCHEMBL2567339 0.84 GPR119 (0.39) CYP11B2GPR119MPOATMDHODH
SCHEMBL1165475 0.84 GPR119 (0.39) CYP11B2GPR119MPOATMDHODH
SCHEMBL1166034 0.79 ATM (0.42) CYP11B2ATMGABRPGABRDGABRA1
SCHEMBL1165213 0.79 ATM (0.41) CYP11B2ATMCHRM4DRD2HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8058289-B2 Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors MERCK SERONO SA (CH) 2011-11-15 — — US disclosed
US-8058289-B2 Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors MERCK SERONO SA (CH) 2011-11-15 — — US disclosed
EP-1786812-B1 PYRIDINE METHYLENE AZOLIDINONES AND THEIR USE AS PHOSPHOINOSITIDE INHIBITORS MERCK SERONO SA (CH) 2011-11-09 — — EP disclosed
CN-101052640-B Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors LABORATROIRES SERONO SA 2011-05-11 — — CN disclosed
US-20110034458-A1 PYRIDINE METHYLENE AZOLIDINONES AND USE THEREOF PHOSPHOINOSITIDE INHIBITORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2011-02-10 — — US disclosed
US-20110034458-A1 PYRIDINE METHYLENE AZOLIDINONES AND USE THEREOF PHOSPHOINOSITIDE INHIBITORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2011-02-10 — — US disclosed
US-7842698-B2 Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors MERCK SERONO S.A. (CH) 2010-11-30 — — US disclosed
US-7842698-B2 Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors MERCK SERONO S.A. (CH) 2010-11-30 — — US disclosed
US-7842698-B2 Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors MERCK SERONO S.A. (CH) 2010-11-30 — — US disclosed
US-20080269227-A1 Pyridine Methylene Azolidinones and Use Thereof Phosphoinositide Inhibitors APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) 2008-10-30 — — US disclosed
US-20080269227-A1 Pyridine Methylene Azolidinones and Use Thereof Phosphoinositide Inhibitors APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) 2008-10-30 — — US disclosed
US-20080269227-A1 Pyridine Methylene Azolidinones and Use Thereof Phosphoinositide Inhibitors APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) 2008-10-30 — — US disclosed
CN-101052640-A Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors APPLIED RESEARCH SYSTEMS (AN) 2007-10-10 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269227-A1 Pyridine Methylene Azolidinones and Use Thereof Phosphoinositide Inhibitors PIK3CD, PIK3CA, PIK3CB CYP11B2 1495/4885GPR119 772/4885MPO 888/4885
US-20110034458-A1 PYRIDINE METHYLENE AZOLIDINONES AND USE THEREOF PHOSPHOINOSITIDE INHIBITORS PIK3CD, PIK3CA, PTEN CYP11B2 1298/4885GPR119 695/4885MPO 848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback